Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Tabelecleucel

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Atara Bio Reports Q3 Financials & Operational Advancements
    Atara Bio Reports Q3 Financials & Operational Advancements

    12 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251112949094/en/Atara-Biotherapeutics-Announces-Third-Quarter-Financial-Results-and-Operational-Progress

    BUSINESSWIRE
    12 Nov 2025
    Share Share
    Pierre Fabre Pharma Acquires Tabelecleucel BLA For EBV+ PTLD
    Pierre Fabre Pharma Acquires Tabelecleucel BLA For EBV+ PTLD

    03 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pierre-fabre-pharmaceuticals-announces-transfer-from-atara-biotherapeutics-of-the-biologics-license-application-bla-for-tabelecleucel-as-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-ebv--302601901.html

    PR NEWSWIRE
    03 Nov 2025
    Share Share
    Atara Biotherapeutics Updates on Ebvallo Regulatory Status
    Atara Biotherapeutics Updates on Ebvallo Regulatory Status

    05 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250505744665/en/Atara-Biotherapeutics-Provides-Regulatory-Updates-on-EBVALLO-tabelecleucel

    BUSINESSWIRE
    05 May 2025
    Share Share
    FDA declines to approve Atara Biotherapeutics' cancer therapy
    FDA declines to approve Atara Biotherapeutics' cancer therapy

    17 Jan 2025

    // PRESS RELEASE

    https://investors.atarabio.com/news-events/press-releases/detail/367/atara-biotherapeutics-provides-regulatory-and-business

    PRESS RELEASE
    17 Jan 2025
    Share Share
    FDA Grants Priority Review For Pierre Fabre's Tabelecleucel BLA
    FDA Grants Priority Review For Pierre Fabre's Tabelecleucel BLA

    18 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pierre-fabre-pharmaceuticals-inc-announces-the-fda-acceptance-and-priority-review-of-the-biologics-license-application-for-tabelecleucel-tab-cel-for-the-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferat-302200702.html

    PR NEWSWIRE
    18 Jul 2024
    Share Share
    FDA Accepts Atara's BLA For Tab-cel With Priority Review
    FDA Accepts Atara's BLA For Tab-cel With Priority Review

    17 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240717492765/en

    BUSINESSWIRE
    17 Jul 2024
    Share Share